VEGFA and glioblastoma: The relevance of vascularization processes in GBM is the rationale of anti-VEGF therapies (i.e., Bevacizumab), but the absence of significant improvements on the mean overall survival reduced the enthusiasm of its use in the clinical practice for GBM [75].